High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: Results and impact on HIV disease

Haematologica

Volumn 89, Issue 9, 2004, Pages 1100-1108

  Gabarre, Jean ^a,d   Marcelin, Anne Geneviève ^f   Azar, Nabih ^a   Choquet, Sylvain ^a   Lévy, Vincent ^a,b   Lévy, Yves ^c   Tubiana, Roland ^d   Charlotte, Frédéric ^d   Norol, Françoise ^f   Calvez, Vincent ^f   Spina, Michele ^e   Vernant, Jean Paul ^a   Autran, Brigitte ^d   Leblond, Véronique ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f NONE

Author keywords

AIDS; Autologous hematopoietic stem cell transplantation; Chemotherapy; HIV; Lymphoma

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BLEOMYCIN; BUSULFAN; CHLORMETHINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOXORUBICIN; EFAVIRENZ; EPIRUBICIN; ETOPOSIDE; LAMIVUDINE; LOPINAVIR; MELPHALAN; METHYLPREDNISOLONE; NELFINAVIR; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; STAVUDINE; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW APLASIA; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOMA; MALE; MORTALITY; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PROGNOSIS; RELAPSE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DNA, VIRAL; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTION; LENGTH OF STAY; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROVIRUSES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 4644234161     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-44.
2. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-6.
3. Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr 1999;21 Suppl 1:S11-S7.
4. Evison J, Jost J, Ledergerber B, Jost L, Strasser F, Weber R. HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy. AIDS 1999;13:732-4.
5. International collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus infected adults. J Natl Cancer Inst 2000;92:1823-30.
6. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730-4.
7. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001;15: 629-33.
8. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-12.
9. Petruckevitch A, Del Amo J, Phillips AN, Johnson AM, Stephenson J, Desmond N, et al. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS 1998; 12:1007-13.
10. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-91.
11. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-63.
12. Thiessard F, Morlat P, Marimoutou C, Labouyrie E, Ragnaud JM, Pellegrin JL, et al. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Cancer 2000;88: 1696-702.
13. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001;112:909-15.
14. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-8.
15. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
16. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-7.
17. Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000;355:1071-2.
18. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, et al. Updated Kiel classification for lymphomas. Lancet 1988;2:292-3.
19. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
20. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-76.
21. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-9.
22. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742-9.
23. Gaspard MH, Maraninchi D, Stoppa AM, Gastaut JA, Michel G, Tubiana N. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988;22: 256-62.
24. 3) receiving IL-2 combined with HAART versus HAART alone (ANRS-082 trial). Antivir Ther 2003;8:233-7.
25. Ferme C, Bastion Y, Lepage, Berger F, Brice P, Morel P, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:543-9.
26. Spina M, Vaccher E, Juzbasic S, Milan I, Nasti G, Talamini R, et al. Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 2001;92:200-6.
27. Levine AM, Tulpule A, Tessman D, Kaplan L, Giles F, Luskey BD, et al. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol 1997;15:1094-103.
28. Tirelli U, Errante D, Spina M, Gastaldi R, Nigra E, Nosari AM, et al. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer 1996;77:2127-31.
29. Bi J, Espina BM, Tulpule A, Boswell W, Levine AM. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 2001;28:416-21.
30. Huzicka I. Could bone marrow transplantation cure AIDS?: review. Med Hypotheses 1999;52:247-57.
31. Gabarre J, Leblond V, Sutton L, Azar N, Jouan M, Boccaccio C, et al. Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma. Bone Marrow Transplant 1996;18:1195-7.
32. Molina A, Krishnan AY, Nademanee A, Zabner R, Sniecinski I, Zaia J, et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000;89: 680-9.
33. Krishnan A, Molina A, Zaia J, Nademanee A, Kogut N, Rosenthal J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001;98:3857-9.
34. Krishnan A, Zaia J, Molina A. Stem cell transplantation and gene therapy for HIV-related lymphomas. J Hematother Stem Cell Res 2002;11:765-75.
35. Law P, Lane TA, Gervaix A, Looney D, Schwarz L, Young D, et al. Mobilization of peripheral blood progenitor cells for human immunodeficiency virus-infected individuals. Exp Hematol 1999;27:147-54.
36. + stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000;181:148-57.
37. Campbell TB, Sevin A, Coombs RW, Peterson GC, Rosandich M, Kuritzkes DR, et al. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood 2000;95: 48-55.
38. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000;18:972-80.